Verimatrix Launches XTD Velocity Partner Alliance to Accelerate Global Channel Sales
Risk Associates, a Middle East leader, joins the partner program to drive Verimatrix XTD app protection, threat detection & Response managed services to their customers
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of the Verimatrix XTD Velocity Partner Alliance, a global channel sales program designed to empower partners with best-in-class application protection solutions. As part of this initiative, Risk Associates, a leading Managed Security Services Provider (MSSP), has joined the program to offer Verimatrix XTD Enterprise Suite to banks and enterprises across Australia, Bahrain, Saudi Arabia, and the UAE.
The XTD Velocity Partner Alliance, spearheaded by Simon Emery, Global Head of Strategic Partnerships at Verimatrix, provides resellers, MSSPs, system integrators, and cybersecurity firms with comprehensive resources to deliver AI-powered mobile app shielding, endpoint threat detection, and response solutions. The program enhances channel sales by offering:
- Resell XTD & Deliver Managed Services – Offer 24/7 app hardening with AI-driven threat detection to stop cyberattacks.
- Expert Training & Certification – Gain the skills to deploy and integrate Verimatrix XTD with confidence.
- Marketing & Sales Power – Access co-branded campaigns, deal registration, and exclusive marketing funds.
- Innovate & Collaborate – Partner on cutting-edge security solutions through joint development and certification.
“With the Verimatrix XTD Velocity Partner Alliance, we're redefining how cybersecurity providers and channel partners collaborate to accelerate app protection at scale,” said Jon Samsel, Global Head of Cybersecurity Business at Verimatrix. “Our expanded partnership with Risk Associates has already resulted in six banks choosing Verimatrix to safeguard their applications—and we’re just getting started. Strategic alliances like this ensure that financial institutions can leverage our award-winning technologies to protect their app code, customer data, and brand reputation with confidence.”
Having successfully deployed Verimatrix XTD app protection for fintech and banking institutions since last year, Risk Associates brings over 20 years of cybersecurity expertise and serves as a trusted MSSP for top brands and startups across the region.
It’s dedication to shielding businesses from the latest threats, including mobile-based attacks, matches well with the opportunity to offer its customers the Verimatrix XTD suite that powerfully protects mobile app owners from reverse engineering, application repackaging attacks, dynamic modification, man-in-the-device attacks while also providing anti-Frida, anti-emulator and anti-debugger defenses.
“Risk Associates welcomes this partnership with Verimatrix to offer proven protections for vital mobile apps that are relied upon by millions in the regions we serve,” said Aziz A. Rahim, Chief Operating Officer at Risk Associates. “Verimatrix’s powerful yet easily-to-implement XTD technologies provide tremendous value to customers through extensive threat visibility and remediation that is often lacking in vulnerable apps that remain crucial for enterprises and their users.”
As part of the XTD Velocity Partner Alliance, Risk Associates now offers the following Verimatrix XTD platform solutions:
Verimatrix XTD Enterprise includes:
- XTD Protect for iOS
- XTD Protect for Android
- XTD Detection & Response
Additional Verimatrix solutions available for resale include:
- XTD Protect for Desktop/Embedded
- XTD Protect for Web
- XTD Protect Native for iOS
- XTD Protect Native for Android
- XTD Managed Services
For more information on joining the Verimatrix XTD Velocity Partner Alliance, visit https://www.verimatrix.com/partners.
About Risk Associates
At Risk Associates, our passion is simplifying compliance for organizations in an increasingly complex regulatory environment. As a UKAS-accredited certification body, we specialize in offering certifications and assessments that enable businesses to meet international standards, minimize risks, and safeguard their operations. We take pride in our role as PCI GEAR (Global Executive Assessor Roundtable) Advisors, ranking among the top 30 QSA companies globally.
Risk Associate’s industry recognition, encompassing PCI DSS, PCI PIN, PCI P2PE, PCI TSP, PCI SSF, PCI SSLC, PCI ASV, PCI 3DS, CSA STAR, SOC I and II, ISO/IEC 27001, ISO/IEC 27701, ISO/IEC 22301, ISO/IEC 20000, HIPAA, HITRUST, GDPR, SWIFT, MARS-E, and NIST, serves as a testament to our expertise, knowledge and compliance competence. As a Qualified Security Assessor (PCI-QSA) company approved by the Payment Card Industry (PCI) Security Standards Council, we are acknowledged as an industry leader specializing in cybersecurity, compliance, information governance, strategy and training. Our services extend across Australia, Europe, the Middle East, Asia Pacific and North America. Visit www.riskassociates.com. Visit www.riskassociates.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319818660/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom